Last updated: August 26, 2026
CORZIDE is a legacy fixed-dose antihypertensive combining nadolol, a nonselective beta blocker, with bendroflumethiazide, a thiazide diuretic. Its commercial position is weak. The product operates in a mature, largely generic hypertension market, has limited current prescribing relevance, and does not have publicly reported standalone revenue. The principal economic outcome is erosion of branded demand, low-volume generic substitution, and declining strategic value.
What is CORZIDE and what drug class does it belong to?
CORZIDE contains nadolol and bendroflumethiazide in fixed-dose tablet strengths, including 40 mg/5 mg and 80 mg/5 mg presentations. It is indicated for hypertension when combination treatment is clinically appropriate. Nadolol reduces cardiac rate and contractility, while bendroflumethiazide increases urinary sodium and water excretion. (DailyMed, n.d.)
| Product |
Active ingredients |
Therapeutic category |
Dosage form |
| CORZIDE 40/5 |
Nadolol 40 mg; bendroflumethiazide 5 mg |
Antihypertensive |
Oral tablet |
| CORZIDE 80/5 |
Nadolol 80 mg; bendroflumethiazide 5 mg |
Antihypertensive |
Oral tablet |
The product addresses hypertension rather than a specialty or hospital market. Its target population overlaps with patients who can receive separate nadolol and thiazide prescriptions or more commonly used fixed-dose combinations involving an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium-channel blocker, or modern thiazide-type diuretic.
What is the FDA regulatory status of CORZIDE?
CORZIDE is an older FDA-approved prescription product whose commercial availability has contracted substantially. FDA records distinguish discontinued marketing from withdrawal for safety or efficacy reasons. The product's current practical status is therefore best understood as a legacy or discontinued-brand product rather than an actively promoted growth product. (U.S. Food and Drug Administration, n.d.-a)
The FDA label identifies standard beta-blocker and thiazide risks, including bradycardia, hypotension, electrolyte abnormalities, impaired glucose tolerance, bronchospasm risk, and masking of hypoglycemia symptoms. These safety considerations limit use in certain patient groups and make newer first-line combinations more attractive for routine hypertension management. (DailyMed, n.d.)
How does CORZIDE compare with current hypertension treatment guidance?
Current hypertension guidance generally prioritizes thiazide-type diuretics, calcium-channel blockers, ACE inhibitors, and angiotensin receptor blockers as first-line options. Beta blockers are usually reserved for patients with a compelling indication, such as coronary artery disease, prior myocardial infarction, heart failure, or selected arrhythmias. (Whelton et al., 2018)
That positioning creates a structural disadvantage for CORZIDE. Its beta-blocker component can be clinically appropriate for selected patients, but the fixed combination is less aligned with broad first-line hypertension prescribing than combinations based on an ACE inhibitor or angiotensin receptor blocker.
When does CORZIDE lose exclusivity?
CORZIDE's core product and formulation exclusivity are historical rather than commercially relevant. Nadolol and bendroflumethiazide are long-established small molecules. Any original composition, formulation, or product patents associated with the product would have expired many years ago under ordinary U.S. patent terms.
No current high-value exclusivity barrier is evident from the product's age, generic availability, and FDA regulatory history. The main commercial barriers are manufacturing economics, demand fragmentation, product discontinuation, and limited prescriber interest rather than patent protection.
| Exclusivity category |
CORZIDE assessment |
| New chemical entity exclusivity |
Expired |
| Original product patent protection |
Expected to have expired |
| Pediatric exclusivity |
Not commercially material |
| Orphan-drug exclusivity |
Not applicable |
| Biologic exclusivity |
Not applicable |
| Current formulation exclusivity |
No material current barrier identified |
| Biosimilar protection |
Not applicable |
What patents protect CORZIDE and how strong is its patent estate?
CORZIDE has no commercially meaningful active patent estate comparable with newer branded medicines. The product consists of two conventional small-molecule antihypertensive ingredients in a conventional oral tablet. Its historical intellectual-property value would have depended on the original combination and formulation filings, but those protections are too old to prevent generic competition today.
The patent estate should be classified as weak for investment or licensing purposes:
| Patent issue |
Commercial assessment |
| Composition of matter |
Expired or commercially exhausted |
| Fixed-dose combination |
Historical protection only |
| Tablet formulation |
Limited ability to block substitution |
| Method of use |
Low practical value in a crowded hypertension market |
| Manufacturing process |
Potentially relevant only to a specific supplier |
| Patent litigation leverage |
Low |
| Freedom-to-operate risk for generic manufacturers |
Generally low, subject to product-specific diligence |
The absence of a meaningful patent barrier does not guarantee continuous generic supply. Older combination products can experience shortages or market exits because annual volume is too low to support multiple manufacturers.
Is CORZIDE listed in the Orange Book?
The FDA Orange Book historically included CORZIDE-related prescription products under older approved drug applications. Orange Book status must be read together with the FDA's discontinued-drug records because an approved product can remain in regulatory databases after commercial marketing ends. (U.S. Food and Drug Administration, n.d.-b)
For market analysis, the key distinction is between:
- FDA approval history;
- current commercial marketing;
- active Orange Book patent listings; and
- available generic products.
CORZIDE's economic value does not depend on a listed patent. Any residual Orange Book presence is primarily an approval-history issue, not evidence of enforceable exclusivity or meaningful brand power.
How many companies are challenging CORZIDE with Paragraph IV filings?
There is no material current Paragraph IV controversy associated with CORZIDE. Paragraph IV litigation is most relevant when a branded product has active listed patents and a commercially significant market. CORZIDE's age and low market profile reduce the incentive for such challenges.
Generic applicants would more likely pursue ordinary abbreviated new drug application pathways based on bioequivalence and product availability. A Paragraph IV filing would have limited economic value unless the applicant expected a sufficiently large market or identified an unexpired patent with meaningful blocking power.
| Challenge type |
Current commercial relevance |
| Paragraph IV patent challenge |
Low |
| ANDA competition |
Possible, but volume constrained |
| 505(b)(2) reformulation |
Low unless a new clinical or delivery proposition exists |
| Biosimilar competition |
Not applicable |
| Authorized generic competition |
Not material based on available public information |
What is the generic market for nadolol and bendroflumethiazide?
Generic substitution is the principal market dynamic. Nadolol is available as a separate generic beta blocker, while bendroflumethiazide has historically been available as a separate thiazide diuretic. The fixed-dose combination offers prescription convenience but can reduce flexibility when physicians need to adjust one component independently.
The product faces several generic-market constraints:
- Hypertension treatment is highly price-sensitive.
- Physicians can prescribe the two ingredients separately.
- Competing fixed-dose combinations have broader guideline support.
- Pharmacies may prefer products with higher dispensing volume.
- Low demand can leave only one or a small number of suppliers.
- Reimbursement may favor separate generic ingredients over a legacy combination.
For manufacturers, CORZIDE-type products can be unattractive because formulation complexity is modest but market size is limited. A manufacturer must maintain validated supply, packaging, regulatory compliance, and distribution for a product that may generate little gross profit per year.
What is CORZIDE's financial trajectory?
No reliable public source reports standalone CORZIDE revenue, prescription volume, gross margin, or current net sales. Product-level financial disclosure is generally unavailable for legacy drugs with limited commercial activity. Company filings historically report broader pharmaceutical segments rather than individual mature products.
The financial trajectory is therefore best characterized as follows:
| Period |
Financial profile |
| Launch and early commercialization |
Branded combination product with potential convenience premium |
| Patent-protected period |
Higher pricing and stronger manufacturer control |
| Generic-entry period |
Price erosion and substitution |
| Mature market period |
Low-margin, volume-dependent product |
| Current profile |
Limited or negligible branded revenue; uncertain generic revenue |
CORZIDE is unlikely to be a material revenue contributor for a diversified pharmaceutical company. Its value, if any, would arise from a small generic portfolio, a product-line acquisition, or supply-chain consolidation rather than from premium pricing.
What revenue exposure does CORZIDE create for manufacturers?
Revenue exposure is limited. A manufacturer holding the product could face:
- low annual sales;
- dependence on a narrow prescriber base;
- reimbursement pressure;
- substitution by separate nadolol and diuretic prescriptions;
- supply interruption risk;
- low return on regulatory maintenance.
A distributor or generic manufacturer might retain the product as part of a broader hypertension portfolio, but CORZIDE alone would not normally justify a major commercial investment.
What competitive products affect CORZIDE demand?
CORZIDE competes with both therapeutic substitutes and ingredient-level alternatives.
Direct and indirect competitors
| Competitive option |
Competitive effect |
| Generic nadolol plus separate diuretic |
Prescribing flexibility and often lower cost |
| Hydrochlorothiazide combinations |
Broad historical use and generic availability |
| ACE inhibitor/thiazide combinations |
Stronger alignment with common guideline pathways |
| ARB/thiazide combinations |
Widely used and often preferred for tolerability |
| Calcium-channel blocker combinations |
First-line positioning in many patients |
| Single-agent modern therapy |
Avoids unnecessary beta-blocker exposure |
The strongest competitive pressure does not come from another branded product. It comes from therapeutic substitution and the ability to prescribe each component separately.
What formulation and manufacturing barriers protect CORZIDE?
The formulation barrier is low. CORZIDE is an immediate-release oral combination tablet rather than a complex injectable, extended-release system, inhaled product, or biologic. The technical requirements are conventional:
- control of two active ingredients;
- content uniformity;
- dissolution performance;
- stability of the finished tablet;
- packaging and labeling controls;
- bioequivalence or applicable regulatory support.
Manufacturing economics may still limit competition. Small-volume products can have unattractive batch sizes, raw-material procurement costs, quality-control expenses, and inventory requirements. These are operational barriers, not durable intellectual-property protections.
What litigation and settlement agreements affect CORZIDE?
No major current patent litigation or commercially significant settlement agreement is associated with CORZIDE in the public record reviewed for this analysis. The product's patent age and limited market reduce the likelihood of modern brand-generic litigation.
Historical litigation, if any, would have to be evaluated against the relevant sponsor, NDA, patent, and court docket. It would not materially change the current commercial assessment unless an unexpired enforceable patent or an active supply dispute existed.
What is the generic launch risk for CORZIDE?
Generic launch risk is asymmetric. The risk of a new entrant materially damaging a branded CORZIDE business is low because the branded market is already mature and commercially weak. The greater risk is supply instability if existing manufacturers withdraw.
A generic entrant would likely pursue one of three strategies:
- compete on price for a small established market;
- maintain the product as part of a broader generic cardiovascular portfolio; or
- enter only after confirming sufficient pharmacy and wholesaler demand.
The likely launch outcome is limited share capture rather than a major market event. Pricing could decline further, but the absolute revenue impact would remain small.
What licensing deals could increase CORZIDE's value?
A conventional licensing transaction is unlikely to create significant value. The product has no obvious proprietary delivery technology, new indication, or active exclusivity period. Potential transactions would be operational rather than innovation-driven:
- acquisition of an abbreviated application;
- transfer of manufacturing rights;
- regional commercialization rights;
- inclusion in a generic portfolio;
- supply and distribution agreements.
A buyer would need to value the product on verified net sales, manufacturing cost, regulatory-maintenance cost, supply reliability, and channel access. A royalty-based deal would likely have limited economics unless the product retains a concentrated regional market.
How does CORZIDE compare with newer antihypertensive combinations?
| Criterion |
CORZIDE |
Modern ACE inhibitor/ARB combination |
| Active components |
Beta blocker plus thiazide |
ACE inhibitor or ARB plus diuretic |
| Broad first-line positioning |
Limited |
Generally stronger |
| Titration flexibility |
Lower because of fixed pairing |
Also limited in fixed dose, but broader use |
| Generic competition |
Mature |
Mature |
| Patent value |
Minimal |
Product-specific, often expired for older agents |
| Commercial growth |
Low |
Higher where guideline adoption and prescribing volume support it |
| Biosimilar relevance |
None |
None |
| Manufacturing complexity |
Low |
Low to moderate |
CORZIDE can remain clinically relevant for selected patients, but its commercial profile is weaker than that of fixed-dose combinations built around guideline-preferred renin-angiotensin system blockers.
Key Takeaways
- CORZIDE combines nadolol and bendroflumethiazide for hypertension.
- Its commercial position is that of a legacy antihypertensive product.
- No meaningful current patent or regulatory exclusivity is apparent.
- Paragraph IV litigation and biosimilar risk are not material.
- Revenue is not publicly reported on a standalone basis and is likely limited.
- The main threats are therapeutic substitution, generic pricing, and product discontinuation.
- Manufacturing complexity is low, but low volume can create supply and profitability problems.
- Any transaction would likely depend on portfolio fit, verified sales, and supply economics rather than patent value.
FAQs About CORZIDE Market Value and Exclusivity
Is CORZIDE still commercially available in the United States?
Commercial availability appears limited and may vary by manufacturer, wholesaler, pharmacy, and product strength. FDA approval history does not establish continuous current distribution.
Does CORZIDE have generic equivalents?
Generic competition can occur through products containing the same active ingredients or through separate prescriptions for generic nadolol and a thiazide diuretic. Exact product availability depends on current FDA-approved and marketed products.
Can a company relaunch CORZIDE profitably?
A relaunch would require verified demand, reliable supply, favorable reimbursement, and low regulatory-maintenance costs. Patent exclusivity would not provide the principal economic rationale.
Is CORZIDE appropriate for first-line hypertension treatment?
Its beta-blocker component limits broad first-line use. Current treatment guidelines generally prioritize thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers, with beta blockers used selectively. (Whelton et al., 2018)
Does CORZIDE have biosimilar competition?
No. CORZIDE is a small-molecule oral drug, so the relevant competitive pathway is generic substitution, not biosimilar development.
References
-
DailyMed. (n.d.). Corzide: Nadolol and bendroflumethiazide tablet, film coated. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/ADA/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
